Advicenne
Research Advicenne (ALDVI) on Bullrun: market cap EUR 26.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALDVI
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 26.03M
- Financial periodFY2025
- RevenueEUR 6.01M
- Revenue growth20.8%
- Net income-EUR 9.53M
- Free cash flow-EUR 4.11M
- Gross margin-15.4%
Valuation Snapshot
latest market cap is EUR 26.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 6.01M | -EUR 9.53M | -EUR 4.11M | -15.4% | n/a | EUR 1.35M | EUR 19.00M | -EUR 26.37M |
| FY2024 | EUR 4.97M | -EUR 6.46M | -EUR 853.00K | -23.6% | -0.31 | EUR 3.25M | EUR 18.19M | -EUR 19.07M |
| FY2023 | EUR 4.46M | -EUR 7.53M | -EUR 7.27M | -49.8% | -0.6 | EUR 4.25M | EUR 18.32M | -EUR 12.61M |
| FY2022 | EUR 3.72M | -EUR 10.27M | -EUR 9.32M | -144.9% | -1.05 | EUR 7.32M | EUR 18.54M | -EUR 10.50M |
| FY2021 | EUR 2.69M | -EUR 12.43M | -EUR 12.82M | 63.8% | -1.34 | EUR 12.69M | EUR 12.37M | EUR 309.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 26.03M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Advicenne's market cap?
Advicenne's market capitalization is EUR 26.03M.
What does Advicenne do?
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.